Luis Jáuregui-Peredo
A5002766172- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Streptococcal Infections and Treatments
- Fungal Infections and Studies
- Cystic Fibrosis Research Advances
- Antifungal resistance and susceptibility
- Antibiotics Pharmacokinetics and Efficacy
- Infective Endocarditis Diagnosis and Management
Mercy St. Vincent Medical Center
2015-2024
Mercy Health
2020-2024
New therapies for complicated skin and structure infections (cSSSIs) are needed because of significant morbidity increasing antimicrobial resistance. Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause cSSSIs. Ceftaroline fosamil, novel parenteral cephalosporin with excellent in vitro activity against Gram-positive pathogens, including MRSA, many Gram-negative was evaluated as therapy cSSSIs multinational Phase III study. The primary study objective to determine...
BACKGROUNDNovel therapeutic approaches are critically needed for Staphylococcus aureus bloodstream infections (BSIs), particularly methicillin-resistant S. (MRSA). Exebacase, a first-in-class antistaphylococcal lysin, is direct lytic agent that rapidly bacteriolytic, eradicates biofilms, and synergizes with antibiotics.METHODSIn this superiority-design study, we randomly assigned 121 patients BSI/endocarditis to receive single dose of exebacase or placebo. All received standard-of-care...
Abstract Background Novel treatments are needed for Staphylococcus aureus bacteremia, particularly methicillin-resistant S. (MRSA). Exebacase is a first-in-class antistaphylococcal lysin that rapidly bactericidal and synergizes with antibiotics. Methods In Direct Lysis of Staph Aureus Resistant Pathogen Trial (DISRUPT), superiority-design phase 3 study, patients bacteremia/endocarditis were randomly assigned to receive single dose intravenous exebacase or placebo in addition standard-of-care...
Oritavancin is a lipoglycopeptide with bactericidal activity against Gram-positive organisms. Its rapid concentration-dependent and long elimination half-life allow single-dose treatment of acute bacterial skin structure infections (ABSSSI). SOLO I II were randomized, double-blind studies evaluating the efficacy safety single 1,200-mg intravenous (i.v.) dose oritavancin versus twice-daily i.v. vancomycin for 7 to 10 days in ABSSSI patients. Safety data from both pooled analysis. The database...
Treatment of complicated skin and structure infection (cSSSI) places a tremendous burden on the health care system. Understanding relative resource utilization associated with different antimicrobials is important for decision making by patients, providers, payers. The authors conducted an open-label, pragmatic, randomized (1:1) clinical study (N = 250) to compare effectiveness daptomycin that vancomycin treatment patients hospitalized cSSSI caused suspected or documented...